Loading clinical trials...
Loading clinical trials...
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Conditions
Interventions
Brentuximab Vedotin
Methotrexate
+1 more
Locations
41
United States
Los Angeles, California, United States
Palo Alto, California, United States
Chicago, Illinois, United States
Boston, Massachusetts, United States
Hackensack, New Jersey, United States
New York, New York, United States
Start Date
June 11, 2012
Primary Completion Date
May 31, 2016
Completion Date
July 6, 2018
Last Updated
January 5, 2021
NCT05414500
NCT06207812
NCT06588868
NCT06716658
NCT06470451
NCT05680558
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions